Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pacira BioSciences, Inc.PCRX · Entity 4928 | SVP & Chief Medical Officer | November 20, 2017 | November 20, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pacira BioSciences, Inc.
Report date November 20, 2017 · Filed November 20, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,823 |
Reported balance
After 2017-11-20 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-11-20 · Sale · Disposed 850 · Balance 16,823 F1: Includes 360 shares of common stock acquired under the issuer's employee stock purchase plan in June 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 360 shares of common stock acquired under the issuer's employee stock purchase plan in June 2017.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 20, 2017 Filed Nov 20, 2017 23:43 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 850 | $41.11 | $34,942.48 |
DisclosureSEC source: 0001209191-17-061873 · doc4.xml · nonDerivative · entry 1 Jones James B · CIK 0001650857 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,823 F1 · balance_after: Includes 360 shares of common stock acquired under the issuer's employee stock purchase plan in June 2017. Read SEC document |
| June 14, 2017 Filed Jun 17, 2017 00:02 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $44.20 | $0.00 |
DisclosureSEC source: 0001209191-17-040678 · doc4.xml · derivative · entry 2 Jones James B · CIK 0001650857 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-14 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 14, 2017 Filed Jun 17, 2017 00:02 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040678 · doc4.xml · nonDerivative · entry 1 Jones James B · CIK 0001650857 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,313 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2018, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 05, 2017 Filed Jun 7, 2017 22:58 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 767 | $43.32 | $33,227.21 |
DisclosureSEC source: 0001209191-17-038417 · doc4.xml · nonDerivative · entry 1 Jones James B · CIK 0001650857 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,813 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. F2 · balance_after: Includes 330 shares of common stock acquired under the issuer's employee stock purchase plan in June 2016. Read SEC document |
| December 07, 2016 Filed Dec 10, 2016 01:22 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $32.35 | $0.00 |
DisclosureSEC source: 0001209191-16-154555 · doc4.xml · derivative · entry 1 Jones James B · CIK 0001650857 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2026-12-07 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.